Vascular Biogenics trades lower after an update on ovarian cancer study
- BySeeking Alpha-
Vascular Biogenics (VBLT), operating as VBL Therapeutics has paused the recruitment of new patients in the U.S
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vascular Biogenics Ltd (VBLT)
NASDAQ
Symbol | Exchange | Currency |
|---|
2.180
+0.040(+1.87%)
After Hours
2.300
+0.120(+5.505%)
- Real-time Data
- Volume:145,261
- Bid/Ask:2.130/2.300
- Day's Range:2.110 - 2.200
VBLT Overview
- Prev. Close
- 2.14
- Day's Range
- 2.11-2.2
- Revenue
- 1.45M
- Open
- 2.11
- 52 wk Range
- 1.02-3.15
- EPS
- -0.53
- Volume
- 145,261
- Market Cap
- 120.09M
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 536,108
- P/E Ratio
- -
- Beta
- 0.98
- 1-Year Change
- 67.19%
- Shares Outstanding
- 55,089,253
- Next Earnings Date
- Aug 16, 2021
What is your sentiment on Vascular Biogenics Ltd?
or
Market is currently closed. Voting is open during market hours.
Vascular Biogenics Ltd News
- Vascular Biogenics prices $25M stock offering
- BySeeking Alpha-
Vascular Biogenics (VBLT) prices public offering of 5.15M shares,to certain investors in lieu thereof pre-funded warrants to purchase 8.05M shares, at $1.90 per share and $1.89...
- Vascular Biogenics proposes capital raise
- BySeeking Alpha-
Vascular Biogenics Ltd Analysis
- Vascular Biogenics (VBLT) Investor Presentation - Slideshow
- BySeeking Alpha-
- Will VBL Continue To Surge Higher?
As of late, it has definitely been a great time to be an investor in VBL Therapeutics (NASDAQ:VBLT) . The stock has moved higher by 5.5% in the past month, while it is also above...
- Implied Volatility Surging For Vascular Biogenics (VBLT) Stock Options
Investors in Vascular Biogenics Ltd. (NASDAQ:VBLT) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 15, 2018 $10.00...
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Neutral | Sell | Sell |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Neutral |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,694.50 | 2,706.10 | 2,685.10 | -21.0 | -0.77% | 1.28M | NASDAQ | |||
| 356.30 | 360.73 | 352.94 | -2.02 | -0.56% | 15.95M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 195.19 | 196.04 | 190.49 | -2.35 | -1.19% | 17.20M | NYSE | |||
| 21.77 | 21.99 | 21.59 | -0.04 | -0.18% | 10.16M | NYSE | |||
| 53.72 | 53.90 | 53.25 | +0.02 | +0.04% | 16.45M | NASDAQ | |||
| 6.56 | 6.62 | 6.46 | +0.020 | +0.31% | 9.53M | NYSE | |||
| 64.68 | 65.10 | 64.04 | -0.09 | -0.14% | 921.47K | NYSE | |||
| 19.63 | 20.17 | 19.44 | -0.29 | -1.46% | 9.74M | NYSE | |||
| 0.6253 | 0.00 | 0.00 | +0.0023 | +0.37% | 544.40K | NYSE | |||
| 1.10 | 1.14 | 1.09 | -0.0500 | -4.35% | 4.58M | NYSE | |||
| 101.81 | 104.05 | 100.76 | -0.76 | -0.74% | 12.29M | NYSE | |||
| 13.71 | 13.83 | 13.46 | -0.02 | -0.15% | 2.73M | NYSE | |||
| 73.67 | 73.81 | 72.72 | +0.91 | +1.25% | 1.63M | NYSE | |||
| 194.99 | 196.30 | 192.63 | -1.63 | -0.83% | 18.30M | NASDAQ |
Vascular Biogenics Ltd Company Profile
Vascular Biogenics Ltd Company Profile
Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi’in, Israel.
Read More
- 2021-03-04 15:55:26waiting good news definitely!👍
- 2021-03-04 12:37:27good job!, congratulations!
- 2021-03-01 18:59:06the Big Risk in Life is not to lose some money , Big Risk It is not investigate and not try to be better..
- 2021-03-01 12:38:06big opportunity if buy and hold..besides science interesting
- 2021-02-25 12:20:02we trust in projects of this company, really amazing ..
- 2021-02-25 09:21:41waiting news about this beautiful company and investing a lot...hold and up!
- 2019-05-31 05:09:29
sorry actually day after tomorrow - 2019-05-31 05:05:28phase 3 report tomorrow
- 2019-01-01 22:54:12new to this stock what's going on with it
- 2019-01-01 22:54:08new to this stock what's going on with it
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.